
Izzet Fresko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6661447/publications.pdf Version: 2024-02-01



177FT EDESKO

#	Article	IF	CITATIONS
1	The Long-Term Mortality and Morbidity of Behçet Syndrome. Medicine (United States), 2003, 82, 60-76.	0.4	635
2	Behçet's syndrome: disease manifestations, management, and advances in treatment. Nature Clinical Practice Rheumatology, 2007, 3, 148-155.	3.2	247
3	Pulmonary artery aneurysms in Behçet syndrome. American Journal of Medicine, 2004, 117, 867-870.	0.6	224
4	Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. Journal of Rheumatology, 2005, 32, 98-105.	1.0	220
5	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. American Journal of Human Genetics, 2013, 93, 298-305.	2.6	143
6	Increased enthesopathy among Behçet's syndrome patients with acne and arthritis: An ultrasonography study. Arthritis and Rheumatism, 2008, 58, 1539-1545.	6.7	94
7	Identification of Susceptibility Loci in <i>IL6</i> , <i>RPS9</i> / <i>LILRB3</i> , and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2015, 67, 1361-1368.	2.9	79
8	Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. Journal of Rheumatology, 2002, 29, 2393-6.	1.0	77
9	Atherosclerosis in Behçet's Syndrome. Seminars in Arthritis and Rheumatism, 2008, 38, 1-12.	1.6	76
10	Behçet's syndrome: a critical digest of the 2014-2015 literature. Clinical and Experimental Rheumatology, 2015, 33, S3-14.	0.4	63
11	Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Research and Therapy, 2012, 14, R27.	1.6	60
12	Behçet's disease as a systemic disease. Clinics in Dermatology, 2014, 32, 435-442.	0.8	54
13	Behçet's disease in the Middle East. Clinics in Dermatology, 1999, 17, 209-223.	0.8	49
14	Behçet's disease. Current Treatment Options in Neurology, 2000, 2, 435-447.	0.7	47
15	Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçet's syndrome patients. International Immunology, 2014, 26, 71-81.	1.8	34
16	Serum mannose-binding lectin levels are decreased in behcet's disease and associated with disease severity. Journal of Rheumatology, 2005, 32, 287-91.	1.0	34
17	Increased Serum Sialic Acid Levels in Primary Osteoarthritis and Inactive Rheumatoid Arthritis. Tohoku Journal of Experimental Medicine, 2007, 213, 241-248.	0.5	26
18	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	2.6	26

Izzet Fresko

#	Article	IF	CITATIONS
19	Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. Rheumatology, 2020, 59, 2264-2271.	0.9	21
20	Infliximab does not suppress the tuberculin skin test (purified protein derivative). Journal of Rheumatology, 2007, 34, 474-80.	1.0	19
21	One year in review 2016: Behçet's syndrome. Clinical and Experimental Rheumatology, 2016, 34, 10-22.	0.4	16
22	Reply to letter by Priori et al commenting on whether Behçet's syndrome patients with acne and arthritis comprise a true subset. Arthritis and Rheumatism, 2010, 62, 305-306.	6.7	12
23	Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. Rheumatology International, 2018, 38, 607-622.	1.5	12
24	One year in review 2019: Behçet's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 3-17.	0.4	12
25	One year in review 2017: Behçet's syndrome. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 3-15.	0.4	11
26	Treatment strategies for Behçet's disease. Expert Opinion on Pharmacotherapy, 2008, 9, 3211-3219.	0.9	10
27	Brief Report: Inadequate Description and Discussion of Enrolled Patient Characteristics and Potential Inter–Study Site Differences in Reports of Randomized Controlled Trials: A Systematic Survey in Six Rheumatology Journals. Arthritis and Rheumatology, 2014, 66, 1395-1399.	2.9	9
28	One year in review 2018: Behçet's syndrome. Clinical and Experimental Rheumatology, 2018, 36, 13-27.	0.4	9
29	The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome. Rheumatology International, 2021, , 1.	1.5	8
30	One year in review 2020: Behçet's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 3-10.	0.4	6
31	Superoxide Dismutase Activity and Glutathione System in Erythrocytes of Men with Behchet's Disease Tohoku Journal of Experimental Medicine, 2002, 198, 191-195.	0.5	5
32	Absence of ANCA in Behçet's syndrome with large vessel involvement. International Journal of Angiology, 2001, 10, 260-262.	0.2	4
33	PDCD1 polymorphisms are not associated with Takayasu's arteritis in Turkey. Clinical and Experimental Rheumatology, 2012, 30, S11-4.	0.4	4
34	Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. Rheumatology International, 2021, , 1.	1.5	3
35	Biosimilar infliximab for Behçet's syndrome: a case series. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 111-115.	0.4	3
36	Outcome of invasive procedures for venous thrombosis in Behçet's syndrome: case series and systematic literature review. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 125-131.	0.4	2

Izzet Fresko

#	Article	IF	CITATIONS
37	Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic review. Rheumatology, 2022, 62, 9-18.	0.9	2
38	SAT0223â€FACTORS ASSOCIATED WITH DAMAGE PROGRESSION IN BEHÇET'S SYNDROME UVEITIS. , 201	19,,.	1
39	Miscellaneous Manifestations of Behçet's Disease. , 2010, , 189-204.		1
40	Behçet's syndrome. , 2011, , 1575-1581.e1.		1
41	One year in review 2021: Behçet's syndrome. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 3-13.	0.4	1
42	Infliximab and primary Sjögren's syndrome: Comment on the article by Mariette et al. Arthritis and Rheumatism, 2004, 50, 4077-4077.	6.7	0
43	240. FACTORS ASSOCIATED WITH DAMAGE PROGRESSION IN BEHçET'S SYNDROME UVEITIS. Rheumato 2019, 58, .	ology,	0
44	THU0298â€INITIAL MANIFESTATIONS AND OUTCOME OF PATIENTS WITH INCOMPLETE BEHÇET'S SYNDR 2019, , .	OME. ,	0
45	FRI0279â€MYCOPHENOLATE MOFETIL IN THE TREATMENT OF MAJOR ORGAN INVOLVEMENT OF PATIENTS WI BEHÇET'S SYNDROME. , 2019, , .	TH	0

46 Endothelial Dysfunction and Atherosclerosis in Behçet's Syndrome. , 2010, , 135-148.